jounce
therapeutics
reports
third
quarter
financial
results
track
begin
enrollment
phase
trial
exclusive
license
agreement
gilead
phase
select
biomarker
selection
trial
vopratelimab
combination
host
conference
call
webcast
today
cambridge
globe
newswire
jounce
therapeutics
nasdaq
jnce
company
focused
discovery
development
novel
cancer
immunotherapies
predictive
biomarkers
today
reported
financial
results
third
quarter
ended
september
provided
corporate
update
jounce
made
continued
progress
quarter
proud
work
team
done
initiate
next
clinical
study
select
move
lead
macrophage
program
inhibitor
receptor
towards
clinic
notably
also
entered
license
agreement
gilead
program
said
richard
murray
chief
executive
officer
president
jounce
therapeutics
broad
pipeline
clinical
preclinical
programs
targets
naïve
experienced
patient
populations
allowing
potential
extend
clinical
benefit
individuals
previously
benefited
io
therapy
look
forward
leveraging
expertise
io
pipeline
goal
bringing
right
immunotherapies
right
pipeline
update
clinical
programs
vopratelimab
initiated
phase
select
trial
vopratelimab
jounce
initiated
randomized
phase
select
trial
evaluate
vopratelimab
combination
inhibitor
versus
alone
immunotherapy
naïve
tis
vopra
second
line
nsclc
patients
jounce
expects
enroll
approximately
patients
outside
expects
report
clinical
data
late
jounce
initiated
randomized
phase
select
trial
evaluate
vopratelimab
combination
inhibitor
versus
alone
immunotherapy
naïve
tis
second
line
nsclc
patients
jounce
expects
enroll
approximately
patients
outside
expects
report
clinical
data
late
reported
interim
analysis
data
phase
emerge
trial
announced
expansion
enrollment
interim
analysis
emerge
phase
clinical
trial
ipilimumab
vopratelimab
combination
meet
criteria
expansion
study
overall
survival
biomarkers
continue
evaluated
preclinical
development
programs
track
initiate
phase
clinical
trial
enrollment
phase
dose
escalation
trial
potential
first
class
antibody
targets
leukocyte
immunoglobulin
like
receptor
macrophages
expected
begin
enrollment
phase
dose
escalation
trial
potential
first
class
antibody
targets
leukocyte
immunoglobulin
like
receptor
macrophages
expected
begin
new
preclinical
data
presented
society
immunotherapy
cancer
sitc
annual
meeting
november
jounce
present
additional
preclinical
data
sitc
annual
meeting
poster
include
data
informing
indication
selection
biomarker
strategies
maximize
potential
therapeutic
benefit
patients
solid
tumor
malignancies
november
jounce
present
additional
preclinical
data
sitc
annual
meeting
poster
include
data
informing
indication
selection
biomarker
strategies
maximize
potential
therapeutic
benefit
patients
solid
tumor
malignancies
established
exclusive
license
agreement
gilead
development
commercialization
september
jounce
announced
exclusive
license
agreement
providing
gilead
worldwide
rights
jounce
highly
selective
potential
antibody
designed
selectively
deplete
immunosuppressive
regulatory
cells
transaction
closed
october
jounce
received
million
cash
including
million
equity
investment
terms
agreement
jounce
continues
progress
ind
clearance
track
ind
filing
first
half
third
quarter
financial
results
cash
position
september
cash
cash
equivalents
investments
million
compared
million
december
decrease
cash
cash
equivalents
investments
primarily
due
operating
expenses
incurred
period
included
september
cash
balance
million
received
upon
closing
gilead
agreements
october
september
cash
cash
equivalents
investments
million
compared
million
december
decrease
cash
cash
equivalents
investments
primarily
due
operating
expenses
incurred
period
included
september
cash
balance
million
received
upon
closing
gilead
agreements
october
license
collaboration
revenue
jounce
recognize
revenue
third
quarter
license
collaboration
revenue
recognized
third
quarter
comprised
million
cash
revenue
related
jounce
license
agreement
celgene
million
revenue
recognition
related
jounce
first
strategic
collaboration
celgene
ended
july
jounce
recognize
revenue
third
quarter
license
collaboration
revenue
recognized
third
quarter
comprised
million
cash
revenue
related
jounce
license
agreement
celgene
million
revenue
recognition
related
jounce
first
strategic
collaboration
celgene
ended
july
research
development
expenses
research
development
expenses
million
third
quarter
compared
million
period
increase
research
development
expenses
primarily
due
increased
expenses
external
clinical
regulatory
costs
associated
select
clinical
trial
increased
employee
compensation
costs
research
development
expenses
million
third
quarter
compared
million
period
increase
research
development
expenses
primarily
due
increased
expenses
external
clinical
regulatory
costs
associated
select
clinical
trial
increased
employee
compensation
costs
general
administrative
expenses
general
administrative
expenses
million
third
quarter
compared
million
period
increase
general
administrative
expenses
primarily
due
increased
employee
compensation
costs
general
administrative
expenses
million
third
quarter
compared
million
period
increase
general
administrative
expenses
primarily
due
increased
employee
compensation
costs
net
loss
income
net
loss
million
third
quarter
resulting
basic
diluted
net
loss
per
share
net
income
million
period
resulting
basic
net
income
per
share
diluted
net
income
per
share
increase
net
loss
primarily
attributable
license
collaboration
revenue
third
quarter
increase
operating
expenses
financial
guidance
based
current
operating
development
plans
jounce
continues
expect
gross
cash
burn
operating
expenses
capital
expenditures
full
year
approximately
million
million
jounce
expects
existing
cash
cash
equivalents
investments
september
combined
proceeds
gilead
sufficient
enable
funding
operating
expenses
capital
expenditure
requirements
conference
call
webcast
information
jounce
therapeutics
host
live
conference
call
webcast
today
et
access
conference
call
please
dial
domestic
international
refer
conference
id
live
webcast
accessed
events
presentations
investors
media
section
jounce
website
webcast
archived
made
available
replay
jounce
website
approximately
two
hours
call
available
days
jounce
therapeutics
jounce
therapeutics
immunotherapy
company
dedicated
transforming
treatment
cancer
developing
therapies
enable
immune
system
attack
tumors
provide
benefits
patients
approach
jounce
currently
multiple
development
stage
programs
ongoing
simultaneously
advancing
additional
assets
robust
discovery
engine
based
translational
science
platform
jounce
advanced
product
candidate
vopratelimab
monoclonal
antibody
binds
activates
icos
currently
studied
select
phase
trial
inhibitor
intended
combination
use
select
trial
jounce
broader
pipeline
jounce
next
development
stage
product
candidate
receptor
antagonist
shown
reprogram
tumor
associated
macrophages
state
phase
trial
evaluating
planned
begin
enrollment
fourth
quarter
additionally
jounce
exclusively
licensed
worldwide
rights
monoclonal
antibody
targeting
designed
selectively
deplete
regulatory
cells
tumor
microenvironment
gilead
sciences
information
please
visit
cautionary
note
regarding
statements
various
statements
release
concerning
jounce
future
expectations
plans
including
without
limitation
jounce
expectations
regarding
timing
initiation
progress
results
release
data
clinical
trials
jounce
product
candidates
including
vopratelimab
may
constitute
statements
purposes
safe
harbor
provisions
private
securities
litigation
reform
act
federal
securities
laws
subject
substantial
risks
uncertainties
assumptions
place
reliance
statements
often
include
words
expect
look
forward
similar
terms
variations
terms
negative
terms
although
jounce
believes
expectations
reflected
statements
reasonable
jounce
guarantee
outcomes
actual
results
may
differ
materially
indicated
statements
result
various
important
factors
including
without
limitation
risks
pandemic
may
disrupt
jounce
business
global
healthcare
system
severely
anticipated
may
effect
delaying
enrollment
completion
jounce
clinical
trials
delaying
timelines
data
disclosures
regulatory
submissions
product
candidates
jounce
ability
successfully
demonstrate
efficacy
safety
product
candidates
jounce
ability
successfully
manage
clinical
trials
development
plans
product
candidates
companion
complementary
diagnostics
management
jounce
supply
chain
delivery
drug
product
materials
use
clinical
trials
actions
regulatory
agencies
may
affect
initiation
timing
progress
preclinical
studies
clinical
trials
jounce
product
candidates
risks
fully
discussed
section
entitled
risk
factors
jounce
recent
annual
report
form
filed
securities
exchange
commission
well
discussions
potential
risks
uncertainties
important
factors
jounce
subsequent
filings
securities
exchange
commission
statements
speak
date
made
jounce
undertakes
obligation
update
revise
publicly
statements
whether
result
new
information
future
events
otherwise
jounce
therapeutics
condensed
consolidated
statements
operations
unaudited
amounts
thousands
except
per
share
data
three
months
ended
september
nine
months
ended
september
revenue
license
collaboration
party
operating
expenses
research
development
general
administrative
total
operating
expenses
operating
loss
income
income
net
loss
income
provision
income
taxes
provision
income
taxes
net
loss
income
net
loss
income
per
share
basic
net
loss
income
per
share
diluted
common
shares
outstanding
basic
common
shares
outstanding
diluted
jounce
therapeutics
inc
selected
condensed
consolidated
balance
sheet
data
unaudited
amounts
thousands
september
december
cash
cash
equivalents
investments
working
capital
total
assets
total
stockholders
equity
investor
media
contacts
malin
deon
mdeon
mark
yore
myore
